| P/E (FY) | — | Sales (TTM) | $18.4M |
| Earnings (TTM) | -$125.4M | ROE | −181.56% |
| Net Margin | −679.16% | ROIC | −318.72% |
| Debt / Equity | 0.30 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −45.99% |
Alector, Inc. is a clinical-stage biotechnology company developing therapies to counteract neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational monoclonal antibody for neurodegenerative diseases; AL137, an anti-amyloid beta antibody for Alzheimer's disease; and AL050, a GCase enzyme replacement therapy for Parkinson's disease and Lewy body dementia. The preclinical and research pipeline includes siRNA candidates targeting tau, alpha-synuclein, and NLRP3.
| Market Cap | $168.8M | Trading Days | 1874 |
| 52W High | 3.40 |
| 52W Low | 1.09 |
| % Off High | −55.29% |
| YTD | −2.56% | 1Y | −13.64% |
| 3Y | −76.14% | 5Y | −95.02% |
| Since incept. (ann.) | −28.17% |
| Ann. Volatility (1Y) | 103.56% | Ann. Volatility (3Y) | 91.45% |
| Sharpe (1Y) | 0.41 | Sharpe (3Y) | −0.04 |
| Max Drawdown (1Y) | −65.66% | Max Drawdown (3Y) | −89.69% |
| Beta (3Y, vs SPY) | 1.12 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M | — |
| TNYA | Tenaya Therapeutics, Inc. | $164.1M | — |
| IVVD | Invivyd, Inc. | $174.8M | — |
| BCDA | BioCardia, Inc. | $180.0M | — |
| ALGS | Aligos Therapeutics, Inc. | $181.1M | — |
| ACOG | Alpha Cognition Inc. | $183.1M | — |
| VYGR | Voyager Therapeutics, Inc. | $183.7M | — |
| LENZ | LENZ Therapeutics, Inc. | $184.4M | — |
| DTIL | PRECISION BIOSCIENCES INC | $185.0M | — |
| PLX | Protalix BioTherapeutics, Inc. | $187.7M | — |
| CRIS | CURIS INC | $188.3M |
| — |
| CRBU | Caribou Biosciences, Inc. | $147.8M | — |
